An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

The treatment of chronic bradycardia, one of the cardiovascular diseases, remains an essential unsolved issue. The objective of this project is to speed up a new drug CARDIX-101 clinical Phase 1IA trial for the treatment of chronic bradycardia and to solve an unmet medical need.

To date, there is no regulatory approved drug of this type available in the U.S or the world. If the new drug CARDIX-101 demonstrated a significant positive effect on chronic bradycardia, it should have a sizeable demand and solve an unmet medical need.

Study Overview

• Status: Not yet recruiting
• Conditions: Bradycardia
• Intervention / Treatment: Drug: CARDIX-101A, CARDIX-101B, CARDIX-101C

Detailed Description

Following FDA and ICH Good Clinical Practice (GCP) guidance, a clinical Phase I study titled "A Single Ascending Dose Clinical Study to Establish Safety and Tolerability of CARDIX-101 in Bradycardia Patients" was conducted at the University of California San Diego (UCSD) School of Medicine, Cardiac Electrophysiology Center, and Altman Clinical and Translational Research Institute and was completed in August 2020 under IND# 131775.

The clinical Phase 1 study of CARDIX-101 was completed using eighteen patients with six ascending single-dose levels. There were no adverse effects observed or reported for all participating subjects related to the investigational medicine.

A current clinical Phase IIA study, "An Exploratory Safety and Efficacy Study of CARDIX-101 for the treatment of Chronic Bradycardia," is a multi-center clinical study. The current clinical study is designed to utilize appropriate wearable monitoring devices for today's Decentralized Clinical Trial.

This study will consist of a multi-site clinical exploratory study in chronic bradycardia patients. The study is open-label, and enrollment of a cohort occurs without randomization.

The study investigates three dosage levels of CARDIX-101 (CARDIX-101A, CARDIX-101B, and CARDIX-101C). The initial cohort will be enrolled in a staggered manner. In this way, it will make the clinical study more accessible for the patient to participate.

• Study Type: Interventional
• Enrollment (Anticipated): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: J. Jean WANG, PHD; Phone Number: 7185818026; Email: jwang@cardixtherapeutics.com
• Study Contact Backup: Name: Gerald J Yakatan, PHD; Phone Number: 8582286983; Email: gyakatan@cardixtherapeutics.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The subject has bradycardia (H.R. <60 BPM). The subject's symptoms, if any, such as dizziness, confusion, fatigue, shortness of breath, chest pain, and syncope, are required to be documented in the case report form (CRF) in the screening, treatment, and follow-up periods.
2. The subject has been informed of the investigational nature of this study and has completed a written informed consent form (ICF) in accordance with institutional, local, and national guidelines.
3. The subject is able to return for the safety and efficacy follow up period and provides at least two modes of contact information (e.g., home and mobile phone numbers, address) and contact information for at least one close contact (e.g., family member or friend) to facilitate follow up.
4. The subject is a male or female 18-80 years of age.

Exclusion Criteria:

1. Patients with peptic ulcer disease, seizure disorder, or cardiac arrhythmia with tachycardia are excluded
2. Patients with asthma who are already taking a beta-agonist and/or Theophylline are excluded
3. Pregnancy (all women of childbearing potential, unless surgically sterilized or post-menopausal defined as the cessation of menses for over one year, receive a pregnancy test).
4. Systolic blood pressure is <100 mmHg.
5. Heart rate >60 bpm.
6. Severe bradycardia or sinus pauses, which in the opinion of the P.I. requires urgent pacemaker implantation or A.V. block > 2nd degree, or existing implanted pacemaker.
7. Serum potassium <4.0 mEq/L or mmol/L by the local laboratory at the screening.
8. History of receiving another Class I or Class III antiarrhythmic drug within three days prior to enrollment. Excluded Class I antiarrhythmic drugs include quinidine, procainamide, disopyramide, lignocaine, mexiletine, flecainide, and propafenone. Excluded Class III drugs include dofetilide, sotalol, dronedarone, and ranolazine.
9. There is a history of amiodarone (oral or IV) within 90 days prior to the study.
10. There is native or prosthetic aortic or mitral stenosis with aortic valve area ≤1.0 cm2, or mitral valve area of <1.5 cm2 or any other valvular diseases requiring surgery.
11. There is an ejection fraction of <35% within one year prior to enrollment (most recent measure if more than one).
12. Atrial fibrillation (A.F.) or atrial flutter (AFL) as a result of surgery (postoperative AF/AFL) within 30 days prior to the study.
13. There is a history of electrical cardioversion within seven calendar days prior to the study.
14. There is a history of any polymorphic ventricular tachycardia, including torsade de points.
15. History or family history of long Q.T. syndrome or other inherited arrhythmia syndrome.
16. There is a history of ventricular tachycardia requiring drug or device therapy.
17. Participation in another investigational drug or device trial within 30 days prior to the study. (subjects in registries may participate with the approval of the registry sponsor.)
18. Acute cardiovascular events (myocardial infarction, pulmonary embolism, cerebrovascular accident, unstable angina, or transient ischemic attack) within 90 days prior to enrollment.
19. Psychiatric disorder, active alcohol/drug abuse, or other circumstance or condition that, in the Investigator's opinion, may interfere with any aspect of protocol adherence or a subject's ability to give informed consent.
20. Untreated hyperthyroidism or hypothyroidism.
21. Acute pericarditis.
22. Unrelated illness such as substantial infection, fever, or prescribed antibiotics in the last seven days, acute rheumatic fever, metastatic cancer, severe hepatic disease, or other extreme medical conditions
23. Exclusion of a woman who is breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: To Establish the Safety and Efficacy of CARDIX-101 in Chronic Bradycardia Patients; Treatment Regimen: A total of 20±4 chronic bradycardia subjects with a heart rate (H.R.) average of less than 60 bpm will be enrolled in the study (6±3/cohort). A clinical study period of 14±2-days is planned for each enrollment of patients. Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.

Drug: CARDIX-101A, CARDIX-101B, CARDIX-101C; Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.; Other Names: CARDIX-101

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The primary endpoint	The primary endpoint measures the mean Heart Rate. During the treatment period of 14±2-day, each patient is required to use near-real-time HR/ECG monitoring for a total of 14±2-day with no less than 16±6-hours of monitoring per day. The increase in the clinical study period (14±2 days) for a patient compared to patient heart rate before dosing of CARDIX-101 (either by baseline record for 2-hours or historical patient records for mean Heart Rate of 5-days). The measure results are as follows: Effectiveness/Significance Level 1: H.R. increase 5-10% Effectiveness/Significance Level 2: H.R. increase 10-15% Effectiveness/Significance Level 3: H.R. increase 15-20% Effectiveness/Significance Level 4: H.R. increase ≥20%	The time frame is during medication 14±2 days

Collaborators and Investigators

• Sponsor: Cardix Therapeutics LLC

Study record dates

Study Major Dates

• Study Start (Anticipated): August 1, 2022
• Primary Completion (Anticipated): December 20, 2024
• Study Completion (Anticipated): December 20, 2024

Study Registration Dates

• First Submitted: October 24, 2021
• First Submitted That Met QC Criteria: November 2, 2021
• First Posted (Actual): November 11, 2021

Study Record Updates

• Last Update Posted (Actual): July 19, 2022
• Last Update Submitted That Met QC Criteria: July 18, 2022
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Bradycardia
• Other Study ID Numbers: CARDIX Therapeutics LLC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: There is no plan to make individual participant data available to other research.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No